Galapagos N.V. (GLPGF)
GLPGF Stock Price Chart
Explore Galapagos N.V. interactive price chart. Choose custom timeframes to analyze GLPGF price movements and trends.
GLPGF Company Profile
Discover essential business fundamentals and corporate details for Galapagos N.V. (GLPGF) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
3 Aug 2009
Employees
704.00
Website
https://www.glpg.comCEO
Henry Gosebruch
Description
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company's pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis. In addition, its other pipeline products include GLPG2737, a cystic fibrosis transmembrane conductance regulator that is in Phase 2 clinical trials to treat patients with autosomal dominant polycystic kidney disease; and GLPG0555, a JAK1 inhibitor, which is in Phase 1b for treatment of patients with osteoarthritis. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; and Novartis Pharma AG. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.
GLPGF Financial Timeline
Browse a chronological timeline of Galapagos N.V. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 22 Oct 2025
Revenue estimate is $69.08M.
Earnings released on 23 Jul 2025
EPS came in at -$1.61 falling short of the estimated -$0.23 by -584.09%, while revenue for the quarter reached $65.29M , missing expectations by -5.22%.
Earnings released on 23 Apr 2025
EPS came in at -$2.55 falling short of the estimated -$0.15 by -1.64K%, while revenue for the quarter reached $82.19M , beating expectations by +19.39%.
Earnings released on 12 Feb 2025
EPS came in at $0.40 surpassing the estimated -$0.53 by +175.03%, while revenue for the quarter reached $78.17M , beating expectations by +11.83%.
Earnings released on 30 Oct 2024
EPS came in at -$0.85 falling short of the estimated -$0.17 by -394.37%, while revenue for the quarter reached $66.85M , missing expectations by -7.37%.
Earnings released on 1 Aug 2024
EPS came in at $0.15 surpassing the estimated -$0.07 by +299.95%, while revenue for the quarter reached $83.73M , beating expectations by +22.01%.
Earnings released on 2 May 2024
EPS came in at $1.47 surpassing the estimated -$0.08 by +1.85K%, while revenue for the quarter reached $67.07M , missing expectations by -5.64%.
Earnings released on 22 Feb 2024
EPS came in at $2.62 surpassing the estimated -$2.18 by +220.19%, while revenue for the quarter reached -$229.99M , missing expectations by -384.58%.
Earnings released on 30 Sept 2023
EPS came in at $0.41 surpassing the estimated -$1.09 by +137.88%, while revenue for the quarter reached $126.61M , beating expectations by +42.97%.
Earnings released on 30 Jun 2023
EPS came in at $0.08 surpassing the estimated -$0.81 by +110.38%, while revenue for the quarter reached $163.58M , beating expectations by +39.92%.
Earnings released on 31 Mar 2023
EPS came in at $0.38 surpassing the estimated -$0.97 by +139.47%, while revenue for the quarter reached $194.47M , beating expectations by +74.90%.
Earnings released on 23 Feb 2023
EPS came in at -$3.16 falling short of the estimated -$0.53 by -496.23%, while revenue for the quarter reached $102.46M , missing expectations by -24.00%.
Earnings released on 3 Nov 2022
EPS came in at $0.33 surpassing the estimated -$0.80 by +141.25%, while revenue for the quarter reached $133.01M , beating expectations by +6.18%.
Earnings released on 4 Aug 2022
EPS came in at -$0.29 surpassing the estimated -$0.82 by +64.63%, while revenue for the quarter reached $143.94M , beating expectations by +11.67%.
Earnings released on 5 May 2022
EPS came in at -$0.20 surpassing the estimated -$1.06 by +81.13%, while revenue for the quarter reached $150.82M , beating expectations by +18.08%.
Earnings released on 24 Feb 2022
EPS came in at $0.25 surpassing the estimated -$0.64 by +139.06%, while revenue for the quarter reached $189.32M , beating expectations by +24.95%.
Earnings released on 4 Nov 2021
EPS came in at -$0.99 surpassing the estimated -$1.31 by +24.43%, while revenue for the quarter reached $74.51M .
Earnings released on 5 Aug 2021
EPS came in at -$0.98 falling short of the estimated -$0.87 by -12.64%, while revenue for the quarter reached $165.83M .
Earnings released on 6 May 2021
EPS came in at $0.14 surpassing the estimated -$0.55 by +125.45%, while revenue for the quarter reached $133.96M .
Earnings released on 18 Feb 2021
EPS came in at -$0.88 surpassing the estimated -$0.95 by +7.37%, while revenue for the quarter reached $177.17M .
Earnings released on 5 Nov 2020
EPS came in at -$1.25 falling short of the estimated -$0.60 by -108.33%, while revenue for the quarter reached $154.76M .
GLPGF Stock Performance
Access detailed GLPGF performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.